Skip to main content
ASRT
NASDAQ Life Sciences

Shareholders to Vote on 6.2% Equity Plan Increase and Director Elections

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
7
Price
$19.26
Mkt Cap
$124.134M
52W Low
$7.706
52W High
$20.45
Market data snapshot near publication time

summarizeSummary

Assertio Holdings, Inc. filed its definitive proxy statement, seeking shareholder approval for a 6.2% increase in its equity incentive plan, director elections, and executive compensation.


check_boxKey Events

  • Annual Shareholder Meeting Scheduled

    The company will hold its virtual Annual Meeting of Stockholders on May 5, 2026, at 11:30 a.m. Central Time.

  • Proposed Equity Plan Expansion

    Shareholders will vote on an amendment to increase the shares available under the 2014 Omnibus Incentive Plan by 400,000, representing approximately 6.2% potential dilution of outstanding common stock.

  • Director Elections

    Six directors, including CEO Mark L. Reisenauer and Chairman Heather L. Mason, are nominated for re-election to serve until the 2027 Annual Meeting.

  • Advisory Vote on Executive Compensation

    An advisory 'say-on-pay' vote will be held on the compensation of the named executive officers for fiscal year 2025.


auto_awesomeAnalysis

Assertio Holdings, Inc. has filed its definitive proxy statement (DEF 14A) for its Annual Meeting on May 5, 2026. The most significant proposal for shareholders is the request to increase the number of shares available for issuance under the 2014 Omnibus Incentive Plan by 400,000 shares. This represents approximately 6.2% potential dilution based on current outstanding shares, which is a substantial amount for a company of this market capitalization. While equity incentive plans are crucial for attracting and retaining talent, this level of potential dilution could be a concern for existing shareholders. The filing also details executive compensation, including the negative 'compensation actually paid' for the former CEO due to equity forfeiture upon his separation, and outlines the re-election of six directors and the ratification of the independent auditor.

At the time of this filing, ASRT was trading at $19.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.1M. The 52-week trading range was $7.71 to $20.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ASRT - Latest Insights

ASRT
Apr 21, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
ASRT
Apr 14, 2026, 4:41 PM EDT
Filing Type: 8-K
Importance Score:
8
ASRT
Apr 09, 2026, 8:09 AM EDT
Filing Type: SC TO-C
Importance Score:
9
ASRT
Apr 09, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
10
ASRT
Apr 08, 2026, 5:10 PM EDT
Source: Reuters
Importance Score:
8
ASRT
Apr 08, 2026, 4:04 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
ASRT
Apr 06, 2026, 5:26 PM EDT
Filing Type: DEF 14A
Importance Score:
7
ASRT
Mar 16, 2026, 5:07 PM EDT
Filing Type: 10-K
Importance Score:
8
ASRT
Mar 16, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
ASRT
Mar 13, 2026, 4:11 PM EDT
Source: Reuters
Importance Score:
7